Co-Authors
This is a "connection" page, showing publications co-authored by SALIM VIRANI and ELIZABETH VAUGHAN.
Connection Strength
3.449
-
From Trials to Practice: Implementing a Clinical Intervention in Community Settings. J Prim Care Community Health. 2025 Jan-Dec; 16:21501319251339190.
Score: 0.247
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2025 Feb 06; 27(1):30.
Score: 0.242
-
Highlights of Cardiovascular Disease Prevention Studies?Presented at the 2024 European Society of Cardiology?Congress. Curr Atheroscler Rep. 2024 Dec 02; 27(1):14.
Score: 0.239
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference. Curr Atheroscler Rep. 2024 Aug; 26(8):367-381.
Score: 0.231
-
A review of top cardiology and cardiovascular medicine journal guidelines regarding the use of generative artificial intelligence tools in scientific writing. Curr Probl Cardiol. 2024 Mar; 49(3):102387.
Score: 0.225
-
Global Cardiovascular Research: Gaps and Opportunities. Curr Cardiol Rep. 2023 12; 25(12):1831-1838.
Score: 0.223
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023 12; 25(12):965-978.
Score: 0.223
-
Implementation and Evaluation of a mHealth-Based Community Health Worker Feedback Loop for Hispanics with and at Risk for Diabetes. J Gen Intern Med. 2024 Feb; 39(2):229-238.
Score: 0.221
-
Demographic and Regional Trends of Cardiovascular Diseases and Diabetes Mellitus-Related Mortality in the United States From 1999 to 2019. Am J Med. 2023 07; 136(7):659-668.e7.
Score: 0.215
-
A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents? Curr Cardiol Rep. 2022 06; 24(6):689-698.
Score: 0.199
-
Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs). Am J Cardiol. 2022 06 01; 172:7-10.
Score: 0.198
-
Long-Term Effectiveness of the TIME Intervention to Improve Diabetes Outcomes in Low-Income Settings: a 2-Year Follow-Up. J Gen Intern Med. 2022 09; 37(12):3062-3069.
Score: 0.197
-
Letter to the Editor: Temporal Changes in Cost-Related Medication Nonadherence by Race/Ethnicity and Medicaid Expansion: The Behavioral Risk Factor Surveillance System Survey. Popul Health Manag. 2022 02; 25(1):141-142.
Score: 0.190
-
Mentored implementation to initiate a diabetes program in an underserved community: a pilot study. BMJ Open Diabetes Res Care. 2021 08; 9(1).
Score: 0.190
-
Racial and Geographic Disparities in Internet Use in the U.S. Among Patients With Hypertension or Diabetes: Implications for Telehealth in the Era of COVID-19. Diabetes Care. 2021 01; 44(1):e15-e17.
Score: 0.180
-
Correction to: Built Environment and Cardiovascular Diseases - Insights from a Global Review. Curr Atheroscler Rep. 2025 Mar 24; 27(1):43.
Score: 0.061
-
Built Environment and Cardiovascular Diseases - Insights from a Global Review. Curr Atheroscler Rep. 2025 Mar 05; 27(1):36.
Score: 0.061
-
Going from Primary to Primordial Prevention: Is the Juice Worth the Squeeze? Curr Cardiol Rep. 2024 Oct; 26(10):1135-1143.
Score: 0.058
-
Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022 02 01; 45(2):372-380.
Score: 0.049